202 related articles for article (PubMed ID: 36990046)
21. Precision Targeted Therapy with BLU-667 for
Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
[TBL] [Abstract][Full Text] [Related]
22. 3,6,2',4',5'-Pentahydroxyflavone, an orally bioavailable multiple protein kinase inhibitor, overcomes gefitinib resistance in non-small cell lung cancer.
Sheng Y; Li W; Zhu F; Liu K; Chen H; Yao K; Reddy K; Lim DY; Oi N; Li H; Peng C; Ma WY; Bode AM; Dong Z; Dong Z
J Biol Chem; 2014 Oct; 289(41):28192-201. PubMed ID: 25122774
[TBL] [Abstract][Full Text] [Related]
23. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.
Hook KE; Garza SJ; Lira ME; Ching KA; Lee NV; Cao J; Yuan J; Ye J; Ozeck M; Shi ST; Zheng X; Rejto PA; Kan JL; Christensen JG; Pavlicek A
Mol Cancer Ther; 2012 Mar; 11(3):710-9. PubMed ID: 22222631
[TBL] [Abstract][Full Text] [Related]
24. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
[TBL] [Abstract][Full Text] [Related]
25. An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present).
Acharya B; Frett B
Expert Opin Ther Pat; 2022 Oct; 32(10):1067-1077. PubMed ID: 36198171
[TBL] [Abstract][Full Text] [Related]
26. Preclinical evaluation of the Aurora kinase inhibitors AMG 900, AZD1152-HQPA, and MK-5108 on SW-872 and 93T449 human liposarcoma cells.
Noronha S; Alt LAC; Scimeca TE; Zarou O; Obrzut J; Zanotti B; Hayward EA; Pillai A; Mathur S; Rojas J; Salamah R; Chandar N; Fay MJ
In Vitro Cell Dev Biol Anim; 2018 Jan; 54(1):71-84. PubMed ID: 29197031
[TBL] [Abstract][Full Text] [Related]
27. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
[TBL] [Abstract][Full Text] [Related]
28. Daurinol Enhances the Efficacy of Radiotherapy in Lung Cancer via Suppression of Aurora Kinase A/B Expression.
Woo JK; Kang JH; Shin D; Park SH; Kang K; Nho CW; Seong JK; Lee SJ; Oh SH
Mol Cancer Ther; 2015 Jul; 14(7):1693-704. PubMed ID: 25882311
[TBL] [Abstract][Full Text] [Related]
29. Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.
Suzuki M; Makinoshima H; Matsumoto S; Suzuki A; Mimaki S; Matsushima K; Yoh K; Goto K; Suzuki Y; Ishii G; Ochiai A; Tsuta K; Shibata T; Kohno T; Esumi H; Tsuchihara K
Cancer Sci; 2013 Jul; 104(7):896-903. PubMed ID: 23578175
[TBL] [Abstract][Full Text] [Related]
30. [Advances in the Treatment of RET Fusion-positive Advanced Non-small Cell Lung Cancer].
Gao Q; Su J; Xiao F; Lin X; Yang J
Zhongguo Fei Ai Za Zhi; 2021 Dec; 24(12):853-861. PubMed ID: 34743497
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.
Spartà AM; Bressanin D; Chiarini F; Lonetti A; Cappellini A; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Martelli AM
Cell Cycle; 2014; 13(14):2237-47. PubMed ID: 24874015
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Safety of RET-Specific Kinase Inhibitors in RET-Altered Cancers: A Systematic Review.
Ali MA; Shah SS; Ali R; Bajwa SF; Rehman S; Anwar A; Anwar MY; Saeed M; Mirza N; Aiman W
Cancer Invest; 2023 Sep; 41(8):739-749. PubMed ID: 37782113
[TBL] [Abstract][Full Text] [Related]
33. Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.
Hatem R; Labiod D; Château-Joubert S; de Plater L; El Botty R; Vacher S; Bonin F; Servely JL; Dieras V; Bièche I; Marangoni E
Int J Cancer; 2016 May; 138(10):2510-21. PubMed ID: 26686064
[TBL] [Abstract][Full Text] [Related]
34. Targeting RET alterations in cancer: Recent progress and future directions.
Shabbir A; Kojadinovic A; Shafiq T; Mundi PS
Crit Rev Oncol Hematol; 2023 Jan; 181():103882. PubMed ID: 36481304
[TBL] [Abstract][Full Text] [Related]
35. Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.
Saha D; Ryan KR; Lakkaniga NR; Acharya B; Garcia NG; Smith EL; Frett B
J Med Chem; 2021 Aug; 64(16):11747-11773. PubMed ID: 34402300
[TBL] [Abstract][Full Text] [Related]
36. Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.
Shah KN; Bhatt R; Rotow J; Rohrberg J; Olivas V; Wang VE; Hemmati G; Martins MM; Maynard A; Kuhn J; Galeas J; Donnella HJ; Kaushik S; Ku A; Dumont S; Krings G; Haringsma HJ; Robillard L; Simmons AD; Harding TC; McCormick F; Goga A; Blakely CM; Bivona TG; Bandyopadhyay S
Nat Med; 2019 Jan; 25(1):111-118. PubMed ID: 30478424
[TBL] [Abstract][Full Text] [Related]
37. A dual aurora and lim kinase inhibitor reduces glioblastoma proliferation and invasion.
Rybin MJ; Laverde-Paz MJ; Suter RK; Affer M; Ayad NG; Feng Y; Zeier Z
Bioorg Med Chem Lett; 2022 Apr; 61():128614. PubMed ID: 35151865
[TBL] [Abstract][Full Text] [Related]
38. AT9283 exhibits antiproliferative effect on tyrosine kinase inhibitor‑sensitive and ‑resistant chronic myeloid leukemia cells by inhibition of Aurora A and Aurora B.
Takeda T; Tsubaki M; Genno S; Nemoto C; Onishi Y; Yamamoto Y; Imano M; Satou T; Nishida S
Oncol Rep; 2020 Nov; 44(5):2211-2218. PubMed ID: 33000229
[TBL] [Abstract][Full Text] [Related]
39. Transcriptional targeting of oncogene addiction in medullary thyroid cancer.
Valenciaga A; Saji M; Yu L; Zhang X; Bumrah C; Yilmaz AS; Knippler CM; Miles W; Giordano TJ; Cote GJ; Ringel MD
JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135308
[TBL] [Abstract][Full Text] [Related]
40. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
Kodama T; Tsukaguchi T; Satoh Y; Yoshida M; Watanabe Y; Kondoh O; Sakamoto H
Mol Cancer Ther; 2014 Dec; 13(12):2910-8. PubMed ID: 25349307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
